<DOC>
	<DOCNO>NCT00751257</DOCNO>
	<brief_summary>N-acetylcysteine inexpensive agent benign side effect profile preliminary study human suggest efficacy treatment cocaine dependence . N-acetylcysteine used clinical medicine nearly three decade treat chronic lung condition , acetaminophen overdose , experimentally treat cocaine dependence . It generally safe well tolerate . The present pilot study seek explore safety tolerability , ad lib smoking , visual cue reactivity , smoke reduction rate group nontreatment seek , nicotine dependence smoker willing undergo brief trial oral N-acetylcysteine 1200 mg twice daily .</brief_summary>
	<brief_title>N-Acetylcysteine Smoking Reduction</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Be smoker motivate reduce cigarette usage seek treatment quit smoking time screen . 2 . Be Able give write informed consent present IRBapproved inform consent document 3 . Be male female race , eighteen sixty five year age . 4 . Be stable physical mental health judge interview 5 . Be smoke 10 cigarette per day one year 6 . Have expire CO read â‰¥10 parts/million prior begin study 7 . Test nonpregnant use adequate birth control ( female ) . All female subject urine pregnancy test perform prior first dose study medication . 8 . Be able comply protocol requirement likely complete study treatment . 9 . Live within 50 mile study site 1 . Have current dependence , define DSM IV criterion , psychoactive substance nicotine , alcohol , marijuana physiological dependence alcohol require medical detoxification . 2 . Have history significant hepatic , renal , endocrine , cardiac ( i.e. , arrhythmia require medication , angina pectoris , myocardial infarction , ) , stroke , seizure , neurological , nondrugrelated psychiatric , gastrointestinal , pulmonary , hematologic metabolic disorder . 3 . Have history adverse reaction/hypersensitivity Nacetylcysteine . 4 . Have significant active medical psychiatric illness ( e.g . schizophrenia , suicidal/homicidal ideation within past 30 day ) might inhibit ability complete study might complicate administration NAC . 5 . Used carbamazepine Nitroglycerin within last 14 day medication felt hazardous take NAC 6 . Have current past history asthma and/or occasional daily use Albuterol betaagonist inhaler . 7 . Females pregnant breastfeed 8 . Have medical history condition consider investigator ( ) place subject increase risk . 9 . Not fail actively meet inclusion criterion time screen . 10 . Have history childhood adult seizure cause . 11 . Be currently take medication ( i.e. , betablockers , stimulant medication ) might affect heart rate skin conductance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Nicotine</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>smoke reduction</keyword>
</DOC>